-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 SMLLH2sgFd5k78UnxEMKp8aj4XJ3izCtx2BEvfLI88brknFW5d3YRs7v7n/YUtYn
 H3rR9N8Zxut8A4+zM2aXbQ==

<SEC-DOCUMENT>0001362310-09-006831.txt : 20090508
<SEC-HEADER>0001362310-09-006831.hdr.sgml : 20090508
<ACCEPTANCE-DATETIME>20090508060057
ACCESSION NUMBER:		0001362310-09-006831
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090507
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090508
DATE AS OF CHANGE:		20090508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		09807701

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c85062e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): May 7, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>GEOVAX LABS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>000-52091</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>87-0455038</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>1256 Briarcliff Road N.E.<BR>Emtech Bio Suite 500<BR>Atlanta, Georgia <BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>30306</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(404) 727-0971</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt; text-indent: 4%">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time to time with the
Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward looking statements and information that
are based upon beliefs of, and information currently available to, the registrant&#146;s management as well as estimates and
assumptions made by the registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;,
&#147;estimate&#148;, &#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they relate
to the registrant or the registrant&#146;s management identify forward looking statements. Such statements reflect the
current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and
other factors relating to the registrant&#146;s industry, operations and results of operations and any businesses that may
be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the
underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed,
estimated, expected, intended or planned.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition</B>


<P align="left" style="font-size: 10pt; text-indent: 7%">On May&nbsp;7, 2009 we issued a press release reporting our results of operations for the quarter ended March&nbsp;31, 2009.
A copy of the press release is attached to this Current Report.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>



<P align="left" style="margin-left:7%; font-size: 10pt">Exhibit&nbsp;99.1 Press Release


<P align="left" style="font-size: 10pt"><B>SIGNATURES</B>


<P align="left" style="font-size: 10pt; text-indent: 7%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current
Report to be signed on its behalf by the undersigned hereunto duly authorized.


<P align="left" style="font-size: 10pt">Dated: May&nbsp;8, 2009



<P align="left" style="margin-left:46%; font-size: 10pt">GEOVAX LABS, INC.



<P align="left" style="margin-left:46%; font-size: 10pt">By:<U> /s/ Mark W. Reynolds</U><BR>
Mark W. Reynolds<BR>
Chief Financial Officer<BR>


<P align="center" style="font-size: 10pt">2



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c85062exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><IMG src="c85062p8506201.jpg" alt="(GEOVAX LOGO)">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Contact:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%">Financial Relations Board<BR>
Leslie Loyet<BR>
312.640.6672 or <u>lloyet@mww.com</u><BR>
At The Company<BR>
Robert McNally<BR>
404.727.0971 or <u>rmcnally@geovax.com</u>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">FOR IMMEDIATE RELEASE

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax Labs, Inc. Announces First Quarter Financial Results</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>ATLANTA, GA, May&nbsp;7, 2009 &#151; </B>GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology
company focused on development of an HIV/AIDS vaccine, today announced its financial results for
the three months ended March&nbsp;31, 2009.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax reported a net loss of $861,509 for the three months ended March&nbsp;31, 2009, compared to
$682,510 for the same period in 2008. Net losses were partially offset by grant revenues of
$710,155 and $599,991 for each period, respectively, related to the Company&#146;s grant from the
National Institutes of Health in support of its HIV/AIDS vaccine development activities. As of
March&nbsp;31, 2009, the Company reported cash balances totaling $1,970,971.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Summarized financial information is attached. Further information concerning the Company&#146;s
financial position and results of operations are included in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Management Commentary</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Robert McNally, GeoVax&#146;s President &#038; CEO, commented, &#147;We are pleased with our first quarter
financial results, as we continue to hold the line on our operational expenses and maintain a
steady cash balance position. We are also pleased with our Phase 2a preventative AIDS human trial
commencement of injections in February and are looking forward to our human therapeutic trial
launch later this year.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Dr.&nbsp;McNally continued, &#147;Despite the global financial crisis, we anticipate our financial position
to remain steady during the year, thanks to the National Institutes of Health&#146;s (NIH)&nbsp;National
Institutes of Allergy and Infectious Diseases (NIAID)&nbsp;direct grant to GeoVax towards the research
and development of our vaccines program; human clinical trials support and financial assistance
received from NIH-NIAID through the HIV Trials Network; and our planned use of funding provided by
the common stock purchase agreement with Fusion Capital Fund II, LLC. We expect these funds to
provide the Company with resources to begin our own direct-funded clinical trial in HIV infected,
drug controlled subjects. Planning for this therapeutic trial is underway with a projected start
for later this year.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Operational Highlights &#151; 2009</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In February&nbsp;2009, GeoVax announced the first injections in its Phase 2a Human Clinical Vaccine
Trial for its candidate HIV/AIDS vaccine. The trial, designated HVTN-205, is being conducted by
the HIV Vaccine Trials Network (HVTN). The HVTN, funded by the NIH, is the largest worldwide
clinical trials network dedicated to the development and testing of HIV/AIDS vaccines. The HVTN
has sponsored over 80 Phase 1 trials for the initial evaluation of safety and immunogenicity of
candidate HIV/AIDS vaccines.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MORE</B>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax Labs, Inc.<BR>
Add 1</B>

</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Of these, only five have progressed to Phase 2 trials since 1992. Progressing to Phase 2 was a
significant achievement for GeoVax.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">First injections for the Phase 2a trial were conducted at the HVTN network sites at the University
of Alabama, Birmingham, and Vanderbilt University, Nashville. The trial will include a total of 225
volunteers (150 vaccine recipients and 75 placebo recipients) and take place at 13 HVTN sites: 11
in North America and 2 in South America. Sites in the United States include Emory University,
Atlanta; Harvard Medical School, Brigham &#038; Women&#146;s Hospital and Harvard-Fenway Hospital in Boston;
Vanderbilt University, Nashville; University of Rochester; Fred Hutchinson Cancer Research Center,
Seattle; the San Francisco Department of Public Health; University of Alabama, Birmingham, and
sites at Columbia University, Union Square, and the Bronx in New York City. In South America,
participants are to be enrolled in Peru at sites in Iquitos and Miraflores (Lima).
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About GeoVax Labs, Inc.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax Labs, Inc. is a biotechnology company focused on developing human vaccines for diseases
caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax&#146;s AIDS vaccine
technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are
designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused
by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may
be effective as therapeutics, treatment of people already infected with AIDS virus.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax&#146;s core AIDS vaccine technologies were developed by Dr.&nbsp;Harriet Robinson, Senior V.P. of
Research and Development, through a collaboration of colleagues at Emory University&#146;s Vaccine
Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention
(CDC)&nbsp;and GeoVax.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine
Trials Network (HVTN)&nbsp;based in Seattle, Washington. The HVTN, funded through a cooperative
agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials
program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided
additional support to GeoVax AIDS vaccine development program with a $15&nbsp;million IPCAVD grant
awarded in late 2007.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>Safe Harbor Statement</I></B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>All statements in this news release, not statements of historical fact, are forward-looking
statements. These statements are based on expectations and assumptions on the date of this press
release and are subject to numerous risks and uncertainties which could cause actual results to
differ materially from those described in the forward-looking statements. Risks and uncertainties
include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with
the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be safe for human use,
GeoVax&#146;s vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory
approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine
development, there is development of competitive products that may be more effective or easier to
use than GeoVax&#146;s products, and other factors over which GeoVax has no control. GeoVax assumes no
obligation to update these forward-looking statements, and does not intend to do so. Certain
matters discussed in this news release are forward-looking statements involving certain risks and
uncertainties including, without limitation, risks detailed in the Company&#146;s Securities and
Exchange Commission filings and reports.</I>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>FINANCIAL TABLES FOLLOW</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MORE</B>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax Labs, Inc.<BR>
Add 2</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
Condensed Consolidated Statements of Operations Information<BR>
(amounts in thousands, except per share data)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Three Months Ended</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">March 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2008</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Grant Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">710</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">600</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">857</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">603</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">724</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">706</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,581</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,309</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(862</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(683</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
Condensed Balance Sheet Information<BR>
(amounts in thousands)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">March 31,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Dec. 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2008</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,971</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,191</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">559</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">611</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,530</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,802</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Property, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">128</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">139</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">112</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">115</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,769</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,056</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">292</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">346</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,477</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,710</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,769</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,056</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Shares Outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">749,909</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">747,449</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">###
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c85062p8506201.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c85062p8506201.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#D!$0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`3('H/THV\OP#;R_`,KT!'TR*+I>5A<T=DU]
MX<#VQ^&,TDULG\A[>20OTI[>5OD'H%`!0`4`)D#N!^(%)-6NGIWZ!HGR[/HN
MOW";E'&Y1CG&0,`=3^M.W9:=`:Y5=^ZEU>EA01C@C'L1BC;3;\!)I_"TUTL&
M1VHM;R_`=K>7X"T`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`(<4PND1E@-PP?EXP.3[8`'?WQ2=[.VC#F72U^Q@:]XK\,^$K,7WB?Q!
MHGANR9S&MUKVJV&D6[/UV)/?W$4;28YVAL^U72PN)JWC2HSQ#6ZA%M_<D85L
M5AZ*O6KT\/\`XIQ7ZGE%W^T[\`+!G67XK^#YFC+9&GZD-47Y3@[&TR.=7YX^
M0MR#Z&NVGE&:R<8QRVM!/:\'%?-NR7SL<$\]RFBFGCZ4N7^5N7_I*9Y]KO[<
M/[.VAHYC\77>LNAP(='T/5'>0EE11$]_!:1-N9@%/F`$\9R0#UKAS-=/]C<?
M6I25OOJ(XY<4Y-&ZABKSZ)4ZOSVI]KO<KV/[8WAW688Y_#WP;_:#UZ*0;HI-
M*^&WGPNIY#I/_;(C=64Y!5CD&HEDU>D[5ZE/#)?S5:7Z38EQ%">F&PE7$+^[
M3J+\XHT?^&HM59@L'[-'[2[94%6E^']E;CYAPS!M>.Q?4\D>A/%2LGP[U_M'
M")O76K3NO7W]S19YB-/^$7&_*C4M\O<V'C]IK7P0/^&9OVBB"<'9X.T_*@@G
M)#ZR@Q]#GGIZ']C8?_H98/\`\&T__DP_MS$+_F28Y6_Z<5/_`)62+^TYJ2$B
M?]FO]IB(+_'%\/;&Z7\!!XA+?^.TI9/0BO=S#"-]E6IK\ZB#^W*__0EQR_[@
M5/\`Y6.;]J;2("RZG\&?VB=$@CP\MYJ?PGU06<2)\\DKS6=W/MBC0%W.WA5)
MP:QAE=:$;0G":3TY:M)_^DST-_[:A3G:>#Q<;+_H'KV7W4CQ_P`4?M-V^I_'
M#1-'M/B`_P`-/A;X*T:QU/X@76KV.F6T^O>)->V2Z3X(=+[2[R\T_48;;>]Q
M%$UHT?V+4%>0M;?)[,,HJT,#*I6PKJ5ZK_<I./NJ/-S-V>VVO5N*6LD>+5SQ
M5<PI>QQ,\-AJ#?ME5A.";?+RV3A%Z6DGH^GS^G=)_:'^!6LM%'IGQ9\`RS2*
M'AAD\4:59SS!N088KZYB>7(Q@!<\CIFO">7XWWKX*LHI-WY)=-;Z+3OY'T,,
MVR^;C!9A13DU&*YN6\F]%KW>A[!;W<%S%#/;2QSV\\2S0SP2)-#+'(`Z/%)"
MQ$B,K!@Z;E(/7D9Y94?9MJ491<=TU9KU5M#M4EIR58/TDOT9;7ITV^W(Q^=+
M1:15DO*Q:O\`:M?R'4#"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@#*U?5]-T'3;W5]8U&STK2]-@:YOM0U"XAL[*TMXQF2:YN;AUCAB`ZLS`?
MB:=.+JN,::M=V7^1G5J1PT)5:K_=Q6VUNOD?"?Q1_P""@'PX\*,^G?#[3;OX
MA:H4(74/.?P_X7MF96P3?WEG)>ZE*C^4PCM+`PS++A+H$,5^DP7#.+KQ4JU6
M.&AVE%N6_965NM^;Y'R^.XIPF'3C1HSJ5'\+C**2T\[]?(\)LO&_[>'QXDMM
M1\*:=<^`O#DZ)Y-]8V</@_2'@NB$-VMYXAN[O5-3@0%R9M-$VT*7B5R4![JF
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M_?"?4_V:_$_BRT\(:1^S=?\`@36;JSO;G2KGQ[\'=*TFVU./2H([F[@L-6E6
M])N(K>Y27;.\?RC"Y9@#Y^/I9W@L/.O/-)5(Q<4XTJ];F7,TKZQ@K7??J>GE
M];AS%XJEA:&4*G4GS<LJN'H.*Y82D[OVDWJHM+1Z]MS[9L[&RT^".UL+*VL;
M:!0D-M:016T$*`8"1Q0HJQJ!C```XKYF=:M5ES593E)[N4Y-_>W<^KIX;#4-
M*5&E32Z0IPA^21;QQ@?+@],=QSG\ZQMT@^6W?7;^OF:MJ'2ZZ6TM^14O[A[*
MSN+I()KI[>&69+6W\D7%TZ1NR6UOY\L<?GRN`B;W0%F4$@&G&&JC[1)^EM_R
MW(E4Y8MJ#M9VL_)O;Y'EOPF^,7AOXPZ+JVK^&[76M'FT'7;GPWK6C>)M/M]-
MUS3-3MD@D>*[LK>^G6-62=2A\W+8/R@8SV9C@:N5^P5=)K$I.#C=+7U2U5TW
MIU6IY^6YA3S&%7V5Z<\-/EFI6U6NUKI7L^VQV7C;Q'IO@SPAXF\5:H\<=AX>
MT/4M8NBY"JR65I+/Y2@D;Y)618EC',C2*@!+`'DPD*U:MAL-3J2C6J35I7;2
M7-VOY=$;8ZO3PN%Q&*FE[.G&UK)-R>VK7=I'Q;^R?\#-&\3?#C5/B+\7_#>B
M>+_$?Q?UI?&T]MXBT^RUJVT_3Y%U!M)DL%O(&^SM<KK&JWPDVI-LU=49MJ*J
M_39SFLHUZ>#P4JE"G@(NFU&;2YVHJ7G:\=+MVO9)=?!R/*:,L)+%XZG#$SQU
MJD7)-VC>7+9/W8^[)7Y$E+2][:>Z:O\`LI?L]:M"\,WPN\-VA9BZR:3'=Z3-
M%)U5HFTV[@$3@XV\8!QQ7F4LXQU)V]M-I:6ERR3]5).Z[IZ-:/0]"KDN6U%2
MC'#0I25_>AS4VI6]UIPE%IQ=FFNIQ6H?LNZ]IB*/AA^T%\8/`JQX6WTN_P!=
MD\8>&[2W3A;:STB_>W:%4^15S<R@*&&TD@KK'.*$JCAB\OIU^9ZRA"G2T>^L
M(*5_.Z9C/)<53C_L>8U*+CLI3JU/_2YM?@<O#XE_;'^$:JGB'PCX7^._AFV+
MJ]_X1U!M&\9F$.(H[F6QN;)5FEV*KM:6UC?-OD<&Z"[=O9.EDF-G"&%?]FR4
M;M5'.:;UWE*I9=M.QP^VS_*TWB6\?2W3A&$&KVTM[.^EKWOU\CTSP5^UI\*/
M%FN6OA+4+S5O`?C.XG@L#X4\=Z1>^']035I6,9TF.XG@^RO?^9Y82(SJ\IN(
M5C4O)L7BQF18_#4_:TG"M2>O-"]E'2TKN.SOIW[G?@N(L#B9JE44L+4T5IV^
M)Z6T>_R/I?S6PI4C!4$8^Z<\Y#8Y!!'2O'Y9N/+%\LX[RZ?)>9[_`#04X0M?
MFV:_RN2JS8^[^1Z?I32<5:^L=WL%]6DK<K:_X(NYO[I_/_ZU,`W-_=/Y_P#U
MJ`#<W]W]?_K4`)E_1?\`OK_ZU`!E_1?^^O\`ZU`"Y;^[^1_^M0`9/IMH`,D?
MP]/PZ^V*`#<W]T_G_P#6H`,MV4#ZMC^E`"9?T7_OK_ZU`!E_1?\`OK_ZU`"@
ML/X>GH>.?PH`,G^[M_I^&*`%!_3\.M`#J`"@#\@_V_OBYXSC\91?".RNI=-\
M&Q^']$UW5+6%"DGB#4+VYU*2'[1-D2/IUJ]A;,L*2*IGA'F`J*^UX2R["RI/
M$3?[R%U%;I6MM9=;]^Q^?\6YCB855A(QY</IKMOY7_\`;>XW]BG]F;PIX[TF
MX^*7CRVCU>QL-;FT?P[X:F5DT]YM+BM9+S5-9A25EO8/MK0P061"(K:<[S><
M)$6*N(,XKX>?U*E!1CR7<OM*[DK)7T=E?;9Z$<.Y'2Q,?KM2;Y:<^1+1)V4)
MO=?WK6NC]<HECBA2**-88H8U2.*-0L<4:*%1(T7"A54``#C`P.*^%<G)M\MV
M]KM+5][M'Z"U&E%1I^Y"']V25EVTU^6_0^'/VE[/5/BC\5?@]^S]:ZA=V&@:
MTM]X[\>1VETUM+=^'-"E2*.R?;M699I8+R-(Q(0LI2<QDQ1D_1Y$H9?EF-S:
M&U-.";ON^5:))2WE'6WF?(YW"699GA<G>E&ZG.S2=DF^KM;W7I:^I]`R>(_@
M?\`M,TCPE<:WX)^&EFUEOTK2+B]M=/DN+2T98#=A)3Y]Z5=E5KB4LS,_S,6)
MKRXT\RS.=3$4Z<L0Y.[GR27DE=M+X;)I;>A[KQ&5Y)0I865:&&I4%RQ@W=[W
M>D4WK)M[:]"YX<^,OP:\>:S9:9X5\>^#?$NNQI=W.GV>FZMI]UJ'EQPRK>26
M*><'8?91-O\`)#8C#EL*K$.KEN:4*4JM7"U*5&+BI3Y)6BY/EC=J]KR:5WHV
MUKJ@I9SE>(:IT,73G4DI.,6W!M13E*RFH[13EZ(\-U/]K^SU#5]4L/A5\)_B
M'\7M+T&XELM4\3>%-+N3H27UO(T5Q;6-Q]AN'O)4D'#8BCD#!XV=/FKLIY"^
M2$L5C*6$YM5&=6ES?^`J3:TULTFNNIQU<\E33>$P=7$0B[<T*51QOU5TK;]M
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M#[-(C6[S9`NE0+(>/%Y##!2PWM\4J5.NTHSW@GWT3M'_`('34Z<'Q!B,:L8L
M)@?:U,+]BZC+?56E*.O];G>^"?VE/`'B/X;^(/B!KUR?!K>"C+:^//#.IB>3
M5_"6I0W\]C#87-L+.&XN9+J2`+;[+?<[EH@HECDC3GKY)B:.+IX>E^\IU;.G
M.,H.+B]VY)\L+7U4W%K=I71UX;/L+/!U<1B)1H8C#7]K2E=2A-?9L[WN^S?J
M=7\&OB'XG^*?A:+QGJW@*?P)I.J,)?#=MJ&MC4-4U;272.2VUJ>Q73+==/M+
MA),P@W$K2*GF!?)>*26,PP='+Z_U:GB8UG&"<I0:M";NG3VU:23;C>+YK)W3
M-,IS#'8VC*O6PGU>GSM4XNRYZ=DXU%[[LI<S5G9^[MJBC\8/@%X#^,&@W]CK
M6DV]AX@:&9]$\7V-K;QZWHFILMN8;^*>'RY+Q5>SM`\,SMO2(*C1L%D2\OS?
M$Y;4A:NYT=(SIMNTH=8K?ENGI;KNFM!8_)L'F5.I&5#V-6TG&:LK3:T;T:T=
MF<-^RAXB\>7'ASQOX#^(E[-K/B+X3>.M0\"GQ'*YD;6[&"TM-2T^[DD"+O<V
M-];NI;,GDSP>:?-WA>C/*=&E5H8BA'V<,=#VL5=?:L]4KN+U]Y2>^ACD%6K/
M#XC"5-?[.J>RC.Z][ENM[V>VZ23N?6"@@=-OMZ5XBBH72ZN[]3WDW975G;5#
MJ8!0`F0/;'X8S18':*OLO\P!':BUO(%:UUL+0`F12YEW'8`1V[?AUH373H*U
MO(6F`W<O8]/PQ_A0[1LFTNW0+6MI;M_704$=NGY4;>7_``0VTVL+0`4`)D#C
MIC\,4;>7X"NK\NS09`P.E&VW0+I-1V8M`PH`*`/EC]I#]F?P]\=M&AFBGM_#
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M^(DJZ1!96-S<RVNI7>D:>\TUZUD]IYI?3;@W4TIECFCBDW1!7'[L`>?*IC\M
M4\)AZT\/*G)I\FFNW6SM9+_(]>5/*LTIX?$5:%.M[17;G>^^SL[:._XGQ/\`
M&+X:Z)X5_:7\#^&_@QHFC^$]1UCX/?$>2U@T&T"1S:Y)X8\<00S&&W+%KLVR
M0PHH&2L@*@,`:^JRC%.KE&)>8XJ56,<1ATXU%=."K4F[N^B6KVMIJTCX[.L-
M'#YY@J66X2-"G]6Q5W2;C:7U>K:R2^6Z^>Q[1\$O%MYJ7[-'@7PW\`F\.VWQ
M"TV&VT+Q!I6M7:1R>&]4LY+Z7Q3K.M:<T<DSFYU"UD\MC&JM)JD2AEV%!Y>-
MCAZ6=SEBZ=2>"Y/<C%M))Q5K)5([2O>SWN[:L]?!5,14R&G1P%6G0QJJ^]*:
M3T4I7^Q/=6Z?,^=?BK\!OCE8:!\>?BIXNG\,-?\`B?P?X>M=6T3P:;B22_AT
M[QEX.U'5]7%G%:QQQPKHFA7<MQG'F">9F&Z1FKNH9A@*U?!TJ%*:5&IRP536
MR5K6;E-[*R3;Z=CSL5D^88>.,Q.*Q$9.=YRC1YH\Z;;=THTHZ[O2V_?7[Y^"
M7C/X?S_`OP3J>D:MHMIX<TCP/I2:LK7=M#%H\MAI<*:S#JD<K8MI8KA+III+
M@*&(>1CY;!C\]F=+$/,L2U"2JRG>#4GI!S4HI1T2M&VMNEMM3ZC+:^`>6X>[
MIQPM.G:=*4(_'9J3=D]WO[W6^Y\#6'P^M/B7\-?CI\2/AA$FF>'O!'Q??XD?
M":,65Y'MD\.Z-9W?C!=,M%V&V&IQ6U@L0\N41R:>J-")(S7U5;$/#8G`8+$2
MC:O0C"LE97;22YG9-ZN:2OO)VM=W^/PF"A6P>98JA!P>"K3J8=Z^[;FDN76R
MVB]GLM#J-+N=:_:(TG]I7X^:/HL^B%OA;)\.O`.FW1COM3MUL]&;5?%R6=Y;
MQ>4YNUDEA06\9DQJ4R;U+FL?90R>M@<NE6_=RE*5113C%RDY.FW&[VDZ?E>-
MS7GJYRLQS2G3LZ4(1IWMS*,5'GLTDME/IU/L_P"`?C?X>7WP8\$7_AO6=#L-
M!T;P?H5O>VLFHV</_"/75KID45[;ZP))Q]AD6\2Z+^=L+E'<,58"OG,UP^*I
M9CB(S<Y2G)NGJTE!RM!;K=62T=DFKH^JR7$8"KEN$E3C3I*$'&JN57=1?$^N
MM^;^7IINSYF_9)U3P[K'[2'[36L>%&MV\/W]U!/IMQ:$_9+J'_A(M6:2\MN,
M?9KB;S9D8?*5E!'!`KV<[52&4Y5&O=U;+U^%>G5J_P"IXG#CI_VOG#PRY**F
M]-E;FZ+6VA\[?'$:'XG^+_Q,^(GA#P/K'B#X5>`=9\,_\+F32?$K6.D>.]1M
M[P1_:M.DLFS;P0W8DCE>-Y`KP7%^QA%SY[>IED(4LNI8>O6@L7BH2>'DU>5*
M+BK*+?O::2:CRJUETN>'F=2C4S#&XC#8:?U+"U;8J,7:->2E[THI222ELK\O
M>Q^O?A#Q/X7USP?H/B/P]>6*>&]2TNPNM+EBF@6UAM);:/RK7<LA6&2W`^SO
M$Q!C>!T(&W`^$Q=*I0JU8UHN52$I*33>KO\`%=V>N^NNI^CX.K1K87#/"VI4
MY4J<HPLER1<4XQ:6ETM':^O5[FKJSZA=63V^D&&&>\MIT@U&94GMK$RQ!8;W
M[(P_XF`1I%D$`*K)M"-)&K[QG1]D]Z;22OLM^V_7O^!MB%-04:=50DVDWY=7
MM_D8_@3PE:>#-'_LR"8W]]=WE[K/B#5WB\F?6_$FIS"YUG5KM#++Y,L]X\GE
MP)(4MX$AMH\QVZ8UQ%:I7J051^[2IJ%-?RQC:UK6MN_5W?4PP>$HX6G4]BTI
M3J.51ZWE)WNW=O\`3<[=>E96LDK]#J77U8Q95\PQ+C>BAF4$;E5F=59EZJK-
M'*`2`"8VQTH'MY$M`#&P`<C@<GL!CGKVH2L[I\OD*R?N[)?(B$JJP3Y5)!(&
M_!&`6^Z0.,`],G@G&`<-J2WV^[]"8NFGR0EKO;7;O^).#^A(_*D61R21PQO+
M(R1QQ*SN[L$1$4%G=V8@*BJ"23T`)I<B["YEW'(ZM]S&W"LK*05*MDAE(/0]
MCW[4^51VT!/MI8?0,JF5%!.1'MY8,0N`<X))X&>V3_%2TDD_9R]W;9?J9SE*
M$N55$N7^NQ/&>.A7GCMG(!R/0<]P*$_)QY=+/0T6T7>]U?3I?[A],`H`KS3Q
M6_S2LL2YC4.[I&I>5Q%%&&8C,CR,JJ.Y8#J14N$V_==DNFQ,I1IZVL/1@2,#
M''?(Z]!R!VS],>])0G!J[T70(SC+5*S7R):LH*`"@"(J.X_#I[5S\TK<M].P
MK*][:HBEMX9HY(I8DDBFC:*6.50Z21.K(\<BL"'0J[`JV00Y'<YTH-47>'[N
M5T[K1IK5/[]1R490=.2O%W]U[:[_`'GEUC\&_`>@'59_!NCOX%OM424W%UX-
MOKW08FN@CB"]ETFSGCTV\N89'\Q!<V<Z%AB171F#>C4QM:KRO$S=>$-;2VMU
M6EM&M&>;3RVAAO:?5*2PTJB:YH:.[V>M]F[F]I?A[6DTF71/%6HZ?XUL[FVD
MLKR;4-)ATV34+.==DT>IV,'GVEXTD1\IU2&T1ADM&<FL7B:?/&KA[TIP;<6G
M\+W7*[*VY2P<_92H5W]8I25I0EL^^UM_S/G+Q)^PY\!M>O!>V'AJY\)N^\W-
MOX>U*_M[29WP0YMYIVCA*]`(41<=A7M87BG,L-3]G/DQ#NWSU-)6?3W91T72
MZOYVL>+6X3RRK6E6IQGA$[?NZ=E&-DE=)PE:^[UW;-/X?_L>?#/X;>,=#\<>
M';KQ%'K6@27)LFN-3FGM_*O;2YL+NW>&9W'DRVMY<+@`;3)O4JP#"<9Q+C,;
MA*V"E1I0IUN6_+S7]R<9K>HUO%=#;`\-8/`XRCC85:LJM%34;\MK5*<J<MH+
M>,WU)O'G[''P0\<ZI<ZU)X:F\/:OJ%W+?:KJ'A^]N['^T[B<^8[7=HL[6Q8S
M'S"Z0*2V23DTL-Q-F6%IQI2_?TX64(RVBDK67*T^O4>(X7RRM-SA'V,F[MQL
MM7UU3+?PT_93\!?"CQ3#XJ\*ZGXFBNUL;W3;FSOM5EOM.O[*_6(W-M=VERK+
M(A>")E;.X%!AO6<PSW$8^BDZ$83B^9.+DI1E>]U>6CO_`,`G`</T\MQ;JQQ$
M^2:Y6O=LXOH[1V,O6/V+?@#K'B./Q`?!W]FH\[7>H:+IFHZG8Z/J%PTC2M)+
M9V]XHMM\K;W2V\M7VC<*JAQ-C:>#E0E*TKW4WI+9:-+1[:==KW#%\.8&OB5*
M$4J;2YH:6>MWT6Y]'>'_``;X6\)^'+?PEX;T+3]'\-VD%S;6^C6,(ALHX;QY
M9;M?+'),\D\SR,Q+.TK%B2:\*6)JXC%O$5*CE56BF]]-5Y;J^Q[E/"T<%A/J
MM"BHT;-."O:SWNO,YSX8?##PQ\)O!T'@GPI:20:-;WFJ7RI<.\TKRZM>RW<O
MG.V3(425(1R?D@0<`5OCL=5QM?V_/:5HZWU]U)+7Y$X#+Z&78=X:FE&FV[Q5
MK6E>_P!]SQ?7_P!B[X`:[K<.M_\`"&C22;V:^U+3M(U'4K#3]7FF.Y_M-I#>
MB.U&XR?\>PA)$S@\$8]>AQ'CZ4*D8U/:5)I)S>Z25E>UD[>G34\:?"N7^UIR
MIJ6'HTW)J%.R3YGS.]XRZW>EMV;6F?LN_#_PM=^([GX?SZ]\.X?%.AV^@:U8
M>&M0>.">RM"S1&"2\%Q-I\I6216>TF@+>8W(8Y$1SO$2E1EB*4:\\/+FIRE=
M2C).Z:Y;)-/;3HMS6?#F%IPJ0P->MA/;JU2,7%1FFK-2O"]FG9ZK?='IG@'X
M5^#OAIX-M_`_AO1XET&-;K[7#<HES)JDMX\CW4^J//DWTLWF%2TF?E`084FO
M)Q^8UJV+6(:?M(M.+U]RVUFK:]6^IZF!P%'!X7ZM*SCLT]+WW_R(O`?P9^&?
MPU55\&>$;+0MCS/&1<7U])";AA++]GDU&[G-LKR%B5BV+N+$#YB6UK9KCL2H
M0JUIR@TTT]%I:RTMW?J10RW`X2525*C&$I6::T:O>_WGCG[06OZQX*\=?!#Q
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MNKM9V?2Y9A^.OC:+PS;ZM+\9X)[#QSK]MI&O^+AX$MX=+_9WOCI]YJW_``CT
MNF)8/<^(M3O&>+2H;G5(Q;P2:<UQ<L//5#A+"X.*C>@H^QIIQ7M(?O\`F=^;
MLK+IHTFDUS)HWI8S')U8O$56JE6?-+E=L.E9J*]W1-MI?%MN=;X-^(OC7Q5\
M1-7T/P[K,*ZO;^(HOAK+XRN_#M@K:Y8?#_X9:IK/BCQ!)I\4<:Q;O'GC33)[
M>T$Z11S9C9I;=WC.-7#X*G1<_=32ORIJZ<ZBM%/;W(IJ7>]T=5+$8ZK44(U*
MD9WY4FFERQC)NIM]JRUONUIJ<K<?'7XYWEQ\(?#ME=VFDZOJ&A:-K_\`:>I6
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M!<6\;16VDZ'J&E:W>3PGRY#JEM`6(CG,64<-A(U*;DXQIXB-.I&SOR0=.-23
MLKO5OD2M<J6*S%TJZCSJ=!5:;=K-S511B_7EC)WVLS!_X6W\5O#?COPP?#UP
M=:\!:MXV^*_@WPM\-+#1+."6X\,_"GPY%:MJ2^(EM?.M)Y?$.AW]K9PRJD;?
MVU$9))3&FW>.`PDZ%6',H8BC"B[W5^:K.5X[;Q2M+I:QE4QN94<3A:T74^KS
M>);II/EE&%*+3:WLI-R6SN>B_L[_`!'\?_$#Q0]]J_C>#Q#H-WX%MO%VI:%%
MX;70T\&>(O%NJ116'@NUO7MTN-6M]"M]`UZVENKC,SS7C&3=M3R^3,,+2H87
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MLH4UZ)2B]-;17F=)I7CKX[VEUHYU'Q)::E9:;\4O`FAZO%;^'[5;_7[/Q1X%
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M1_&;5M53Q')X5LX;6Q\/>`_A[HOCUX++1H79#?:=XIUW2K&UEEFD>1X@)6(\
MP+A3HX%1CB+J%*%&$904ES<\VX*6V[Y.=V6B=[/KT5:^9<LJ3I2YYU)\LN5K
MEC'IOM[RWW.6^%_Q*^*-C\.OAG%/XZG\0^*?C;I'C*T\)/JFBHQ\+^.9?$&A
MDG46(EGO[;1--O/%>I3P3,B-%H+VT08O%NK$83#<U:4*?+3PG)*;35IP:G;E
M6GQ2Y8[O?6UFS#!XW&4JE&C.4G/%N48*SO"2]Z3_`/`;O_,_0S28+RTT^SMK
M^];4;RWM+6&YOG@2V:\GB@CCGNV@C^6$SS))+Y8)"^;M'`&?G)M.I-QCR0N^
M5+HNWR/L::<:<(RE><5[SZW9I5)84`-VFL?9OR_KY`)M/M1[.2>C2_KT"UOD
M-*-D8(4`]!D<=^@K6WNN/=6+3235O3R%*'^$X_$BL52<?ALOO$G83R_<_P#?
M3"M8Q22YEJB)<UWROE71?TA=AZ9X]B13E&-O=7*^CV_(45--7::73^D`3'?\
MR:E1DNOXLT;7:WHDOR$V,#P0`#G&3QGVQQ1:2C)1=FV[>5_ZZ![FEX_#MHA0
MGT_EC]*RI4I1C:;YM>[_`%L2U'[*Y7]PNSTP/TK7D4?@7*"OLW<-N..@'X8S
M1R*/PJR"RZ_Y"%#QC`Q^'7\*%"S7+[JZZM7$^?[+Y5V%*G&!@?YY[54D].5\
MMO,24UL[?UZ!L(Z8`[#IBG9=4K^A6GG]]OR$V$'C`''X=<]O>I::E&UDH_+?
MY"45S.ZTLDEKTO\`YD1@(8G"=%.#GAEQ@C`SZ^]-N6J3M%IIK;1JP2A"48J<
M4W!W3M:S3NFMK-:"^0N>54$`<@8*L-N-N!TX[YZ"BFYTUR\S4>BOHM_\R)4:
M3ES>SBI_S62?W[B&UCSPJJ,Y(`&,X(SC'7GCWJU.JOMNZV].PHX;#0C.*H02
MGJ_=6_?U`6ZH,JD8?.[)'1MO!R!GJ%YZX%3*51KE4G_3N6J=&,E*-*,9)632
M28UK4?W8LKC8"BX4A`%(RA*D$<8]3WZ$G/WN6<H\W]Z27W)V%&C1M#GHPE*&
MSY5IZ/2PY+=8L"-(T'.[:H4],#&T`?G0Y5'4DY3;AIRJ[TT[>NI-*A2HI6I1
M4E>[44F]7ULGU$6V$9^0*HQ@X^4D$@MG:H]6]NF>]#E4YK\[Y4M$V]'I9V^\
MJ-&A#F=.A"$I73:BE=/=/R8JVX3A4C0!<84$<NY:4]._!'J<[L\53G/E:E*[
M_P"!9?<ONZ!"E2I_!3C&VUDD,%NZ[MJPJ6&YL;QF3!RQXR>=O/7CV%*,I+V:
M;=J:LEV5MEY$*A3C*5H12E/GDK;_`!7NMKMNY6O--%Y:S6<F5CFM[B!G@N;N
MRN4%PIC9K>\LY(KBTE,4DH\Z"2.5"0T;JPR+]I.-12A)Q6G,N]M8JVJLGK8E
MX:G[.G&5.+E3A.*TT3G%QDUZ]7N<[X<\!Z'X2EOKC18K]KO56LEU+4-;\1>(
M_$NJ7%MIZW8LK3^T_$>IW]TMG;&]N6AM5F6"-[RZD5!)<2M)I7Q%2M!0G+W8
M)J*244KM-Z12W:NWNV9X+!4<%&LJ5-0E5W:;>VWQ;*VEEH=:+?"N-D2\YCP"
M`/E(^;C@EF<';V8]R:P<I>][S5U9:_=^GW'2J<$HKDC[KOLMWN_F)]D3>3Y<
M2C!`(&'`<;I`#C@&18VQW*`G)`JHU:BBDYNZ\[;72[;)M?-]S+ZKATI1]C#E
MG*[5EMH__2TI:=1P@(^\$SW7G;T(R<C)/3J>E2Y2^RVK?U_P_<WY(**CR13T
MOHM;?#]VMMMR)[4@#RMBX*\,6`P'\S/R#.X,2P]PM.4ZGV96M?JUHX<MOS^7
MW&5.A2I+^''9+X4MJCGV7?[_`+R7R&79MV?*QZY!"-ABJ[0,<@#'3`&<D9K.
M//&*BY>MF]>W;;7[S5PIWOR+2_+HM&]_O=F_0Y5O`?AMO%*^-9;![KQ);VTM
MKIUY?ZCJ=];:/%/#]GG_`+#TJ\NY+'P_-<PX2YGTVVM9KD9$\D@)!Z%B*L:4
MJ2FU&=E)+3F2=TG:S=NE_P!$<GU*A[>%?V4>:ES.G_<E)6;2V5TV=@J!"Q`"
MEL$XXR1GD\=>:QU7HME^9UI)>KW_`$'T#"@`H`*`"@`H`*`"@`H`*`"@`H`*
L`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
